Barry D. Liboiron, Ph.D.

University of British Columbia, Vancouver, Vancouver, BC, Canada 
"Barry Liboiron"
Mean distance: 8.84


Sign in to add mentor
Chris Orvig grad student 2002 UBC
 (Biologically relevent physical studies of insulin-enhancing vanadium complexes.)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Liboiron BD, Louie AC, Mayer LD. (2016) Nanoscale complexes - A novel nanotechnology-based platform to optimize combination cancer therapies: Rational development & improved delivery using combiplex® Drug Development and Delivery. 16
Liboiron BD, Mayer LD. (2014) Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy. Therapeutic Delivery. 5: 149-71
Dikanov SA, Liboiron BD, Orvig C. (2013) VO(2+)-hydroxyapatite complexes as models for vanadyl coordination to phosphate in bone. Molecular Physics. 111: 2967-2979
Stern ST, Zou P, Skoczen S, et al. (2013) Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion. Journal of Controlled Release : Official Journal of the Controlled Release Society. 172: 558-67
Feldman EJ, Kolitz JE, Trang JM, et al. (2012) Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leukemia Research. 36: 1283-9
Liboiron BD, Tardi PG, Harasym TO, et al. (2011) Nanoscale Delivery Systems for Combination Chemotherapy Drug Delivery in Oncology: From Basic Research to Cancer Therapy. 2: 1013-1050
Dicko A, Kwak S, Frazier AA, et al. (2010) Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin. International Journal of Pharmaceutics. 391: 248-59
Lim WS, Tardi PG, Dos Santos N, et al. (2010) Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. Leukemia Research. 34: 1214-23
Harasym TO, Liboiron BD, Mayer LD. (2010) Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumvention. Methods in Molecular Biology (Clifton, N.J.). 596: 291-323
Ansell SM, Johnstone SA, Tardi PG, et al. (2008) Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates. Journal of Medicinal Chemistry. 51: 3288-96
See more...